Crispr therapeutics insider trading
Web1 day ago · CRISPR Therapeutics AG (CRSP) closed the last trading session at $45.41, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ... WebInsider trades for Crispr Therapeutics AG (CRSP). Monitor SEC Form 4 Insider Trading Filings for Insider Buying and Selling. Real-time Insider Trading Stock Screener. Long …
Crispr therapeutics insider trading
Did you know?
Web21 hours ago · Cantor Fitzgerald initiated coverage on CRISPR Therapeutics AG CRSP with an Overweight rating and a price target of $72, citing an interesting gene editing play for 2024. The company has an ... WebApr 10, 2024 · Market Holidays Daily Analyst Ratings Daily Insider Trading. Research Tools . ... CRISPR Therapeutics AG engages in the development and …
WebCRISPR Therapeutics Insider Trading History Chart. This chart shows the insider buying and ... WebApr 14, 2024 · CRISPR Therapeutics AG CRSP shares soared 16.3% in the last trading session to close at $50.56. The move was backed by solid volume with far more shares …
WebCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ... WebCrispr Therapeutics AG insider trades are shown in the following chart. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information.
WebApr 13, 2024 · CRSP has an average price target of $84.19 among all 26 analysts with coverage of the stock. That implies an upside of about 68%. However, insider activity over the past three years paints a ...
WebApr 12, 2024 · Kistler Tiffany Companies LLC grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Get Rating) by 439.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission.The firm owned 4,217 shares of the company's stock after acquiring an additional 3,435 shares … flashpoint 10.0 infinityWeb21 hours ago · Cantor Fitzgerald initiated coverage on CRISPR Therapeutics AG CRSP with an Overweight rating and a price target of $72, citing an interesting gene editing play … flashpoint 10WebFeb 27, 2024 · The estimated net worth of Lawrence Otto Klein is at least $1.42 million as of January 15th, 2024. Dr. Klein owns 28,666 shares of CRISPR Therapeutics stock worth … checking account print outWeb16 hours ago · CRISPR Therapeutics AG (NASDAQ:CRSP) is something of a hot-button topic by virtue of its very existence.But one analyst, in particular, is less interested in the controversy than in the potential involved in this biotech stock.The resulting fresh coverage with a positive rating helped send CRISPR up over 16% in Thursday afternoon’s trading. flashpoint 11.1 infinity.exeWeb4 rows · 12/20/2024. Option Execute. Direct. 17,750. $1.81. 279,085. Back to CRSP Overview. Insider ... flashpoint 10 downloadWebApr 3, 2024 · CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell … checking account programsWeb20 hours ago · Cantor Fitzgerald initiated coverage on CRISPR Therapeutics AG (NASDAQ:CRSP) with an Overweight rating and a price target of $72, citing an interesting gene editing play for 2024.; The company has ... flashpoint 10.1 infinity.exe